ArticleBMC cancer2024
Potential involvement of cuproptosis induced by m6A-modified autophagy gene ATG10 in KICH : Cuproptosis induced by m6A-modified ATG10 in KICH.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- N6-Methyladenosine RNA Methylation: A Key Regulator in Male Reproductive Disorders and Urological Cancers.The world journal of men's health · 2026Review
- Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets.Hepatology international · 2025Review
- Subtype cluster analysis unveiled the correlation between m6A- and cuproptosis-related lncRNAs and the prognosis, immune microenvironment, and treatment sensitivity of esophageal cancer.Frontiers in immunology · 2025Article
- Integrated machine learning based on cuproptosis and RNA methylation regulators to explore the molecular model of prostate cancer and provide novel insights to immunotherapy.Journal of Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney Chromophobe (KICH) is the third most prevalent renal malignancy, with research challenges due to a dearth of cell lines and clinical samples. There is no specific treatment regimen tailored exclusively for KICH. This study employed gene expression analysis, immunohistochemistry (IHC), Spearman's correlation, immune cell infiltration assessment, and molecular network construction to investigate the autophagy gene ATG10 in KICH. ATG10 was uniquely downregulated in KICH, predominantly regulated by RNA m6A methylation. This downregulation correlated with patient survival, suggesting a potential tumor-regulatory role. ATG10's involvement in the protein lipidation pathway, essential for cuproptosis, was identified. B cells and CD8 + T cells were key immune cells in KICH tumorigenesis associated with ATG10. Examination of molecular networks identified several key molecules and mechanisms, including ceRNA, interplaying proteins, and transcription factors. Additionally, drug targeting analysis pointed to specific amino acids and metabolites as potential therapeutic agents. This study elucidates the significance of ATG10 in KICH, implicating m6A methylation and cuproptosis as novel targets for therapeutic intervention. The identification of B cells and CD8 + T cells as key immune components, along with specific amino acids, suggests that a combination of targeted immune therapies and dietary interventions could provide a multifaceted approach to KICH treatment. Given the limited understanding of KICH pathogenesis, our analysis has unveiled new theoretical insights and potential clinical significances for KICH, expected to broaden the research horizon in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.